News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major economic releases or central bank updates occurred in the past hour, leaving headline macro risk muted.
  • Global equity markets showed little movement, with volumes light and major indices trading in narrow ranges.
  • Oil and gold prices were stable as no supply shocks or demand signals emerged during the hour.
  • No significant geopolitical incidents or conflict escalations reported that would affect market sentiment.
  • Treasury yields and the dollar were largely unchanged amid the quiet news flow.
  • Corporate newsflow was thin with no major earnings surprises or M&A announcements in the past hour.

Latest Articles

SCWorx Receives Nasdaq Hearings Panel Partial Compliance Letter for the Company’s Continued Listing on the Nasdaq Capital Market

SCWorx Receives Nasdaq Hearings Panel Partial Compliance Letter for the Company’s Continued Listing on the Nasdaq Capital Market

SCWorx Corp. announced it has received a partial compliance letter from the Nasdaq Hearings Panel confirming that it has met the first requirement to maintain its listing on the Nasdaq Capital Market by achieving the minimum bid price for 20 consecutive trading days. The company continues to execute its compliance plan focused on satisfying all Nas…

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics announced that The Lancet has published its Phase 3 HOPE-3 clinical trial results showing Deramiocel significantly slows disease progression in Duchenne Muscular Dystrophy (DMD) patients. The trial met its primary endpoint, demonstrating a 54% slowing of upper limb function decline and cardiac benefits. The company’s Biologics…

Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation

Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation

Smith+Nephew announced that the FDA has granted De Novo classification to its TESSA Spatial Surgery System, an innovative technology that utilizes AI, advanced imaging, and real-time tracking to improve precision in arthroscopic surgeries such as anterior cruciate ligament reconstruction. This regulatory milestone establishes a new FDA category and…

Parsons Plunges After Earnings Miss, $118M of Charges and Deep Guidance Cut

Parsons Plunges After Earnings Miss, $118M of Charges and Deep Guidance Cut

Parsons Corp (PSN) plunged 40.5% to $36.91 intraday, triggering brief volatility halts, after the company reported a disappointing second quarter, announced $118 million of non-recurring charges and sharply trimmed full-year 2026 guidance. The market is reassessing the firm's near-term outlook following an EPS shortfall, a GAAP net loss, and a down…

Romanian Parliament Clears Laws to Release €3 Billion in EU Recovery Aid

Romanian Parliament Clears Laws to Release €3 Billion in EU Recovery Aid

Romania's parliament approved multiple bills during an extraordinary session on Wednesday designed to unlock roughly €3 billion ($3.4 billion) in European Union recovery funds required to help meet this year’s budget deficit target. The measures include administrative code amendments, a performance-based incentive scheme for tax and customs staff, …

PolyPid Gains After FDA Accepts D-PLEX100 NDA, Grants Priority Review

PolyPid Gains After FDA Accepts D-PLEX100 NDA, Grants Priority Review

PolyPid Ltd. shares climbed after the U.S. Food and Drug Administration accepted the company’s New Drug Application for D-PLEX100 and assigned priority review for use in preventing surgical site infections in abdominal colorectal surgery. The agency set a PDUFA target action date of November 28, 2026, moved up about one quarter from the company's p…

Nebius PaaS: Buy Microsoft on Platform Resilience, Not Agentic Noise

Nebius PaaS: Buy Microsoft on Platform Resilience, Not Agentic Noise

Microsoft’s platform-first strategy (Nebius-style PaaS) continues to underpin durable revenue and cash flow even as Copilot and agentic product setbacks create headline volatility. The company’s cash generation, healthy balance sheet, and cloud positioning give investors a margin of safety. This trade idea targets a disciplined entry at $392 with a…

BorgWarner Shares Rise after Win for High-Performance eTurbo System

BorgWarner Shares Rise after Win for High-Performance eTurbo System

BorgWarner shares climbed 2.3% in pre-market trading following an announcement that the company will supply its electrically assisted eTurbo technology to a major European automaker, with series production slated to start in 2029. The unit is built on BorgWarner's 400-volt platform, delivering 20 kW continuous and up to 30 kW peak power at rotation…

Performance Shipping Inc. Reports Financial Results For The Second Quarter and Six Months Ended June 30, 2026

Performance Shipping Inc. Reports Financial Results For The Second Quarter and Six Months Ended June 30, 2026

Performance Shipping Inc. announced financial results for Q2 and the six months ended June 30, 2026, reporting net income attributable to common stockholders of $13.9 million for Q2 and $23.7 million for the first half of 2026. Revenue significantly increased due to new vessel deliveries and acquisitions. The company secured long-term charters at a…